Treatment for high pressure bleeding

Abstract

High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The invention is generally related to emergency medicine. In particular, the invention relates to bleeding and bleeding injuries.[0003]2. Background Description[0004]The morbidity and mortality from penetrating injuries (such as ballistic injuries in combat, knife wounds, penetrating wounds secondary to motor vehicle accidents, etc.) has decreased over the past fifty years. However, some undesirable results remain. Present treatments for high pressure, i.e. arterial, bleeding can cause ischemia that might contribute to limb loss. Tourniquet use can contribute to the need for amputation. This is especially true if there is a significant delay in definitive treatment.[0005]As to military trauma, two characteristics of death due to such trauma are seen. First, early death occurs. Soldiers who die due to injury, die early: about 40% die immediately; 25% die within 5 minutes; 15% die within 15 minutes; i.e., a total of 80% d...

AI Technical Summary

Benefits of technology

The patent describes a method to stop bleeding quickly by using pressure equalization. This is done by enclosing the area around the bleed and applying direct pressure to stop the bleeding. The method is simple, easy and inexpensive compared to other biological products. The invention directly addresses the problem of high pressure by simulating the time-honored treatment of direct pressure. This method can be performed by a medic and the acute dressing is removable for a definitive treatment.

Problems solved by technology

However, some undesirable results remain.

Present treatments for high pressure, i.e. arterial, bleeding can cause ischemia that might contribute to limb loss.

This is especially true if there is a significant delay in definitive treatment.

First, early death occurs.

Such injuries can be associated with rapid blood loss due to vascular disruption.

Despite increasingly aggressive surgical treatment, limb salvage has not improved.

Because trauma occurs most in young people, trauma is the leading cause of life years lost.

However, these current bleeding treatments have significant disadvantages, such as nerve damage, limb ischemia, increased risk of amputation, etc.

Unfortunately, tourniquet use is associated with a variety of complications and difficulties including nerve damage, post-tourniquet syndrome, limb ischemia (distal ischemia), compartment syndromes, pulmonary embolus, increased risk of amputation, and limb wastage.

This typically restarts the bleeding and is difficult for treating personnel to accomplish.

While fibrin products (such as fibrin glue, fibrin sealant and dry fibrin dressing) have been developed and shown to be effective in stopping venous bleeding, such fibrin products do have drawbacks.

Fibrin products have had a tendency to be washed from the wound during high pressure bleeding, relative high cost.

Some fibrin products put the patient at risk of viral exposure.

While the development of “dry” products has increased their potential as alternatives to tourniquets for battlefield treatment, several potential problems remain.

First, these products are relatively expensive because they are made from human blood (requiring a large amount of starting materials and multiple purification processes).

Second, although virally inactivated, the fibrinogen contained in the products comes from multiple human donors and cannot be considered totally safe in terms of viral transmission.

Third, these products must be held in place until bleeding stops or the material may simply wash out of the wound.

The wash-out problem is especially seen when the bleeding is brisk as with arterial involvement.

Also, treatment of bleeding external wounds also has not progressed much, with conventional treatments not offering much beyond simply covering the wound.

There are emerging products that aid in hemostasis (fibrin glue, fibrin sealant, dry fibrin, kitosan, etc.) but most are quite expensive and some carry a risk of viral infection.

Another difficulty of conventional treatments for bleeding is that the patient loses much of his or her own blood, and transfusion is needed.

Blood transfusion suffers from availability problems, purity concerns, etc., and is expensive.

None of the current technologies adequately address the problem of treating high pressure arterial bleeding.

Images